CD19-immunoPET for noninvasive visualization of CD19 expression in B-cell lymphoma patients

Abstract

Cell- and antibody-based CD19-directed therapies have demonstrated great potential for treating B-cell non-Hodgkin lymphoma (B-NHL). However, all these approaches suffer from limited response rates and considerable toxicity. Until now, therapy decisions have been routinely based on histopathological CD19 staining of a single lesion at initial diagnosis or relapse, disregarding heterogeneity and temporal alterations in antigen expression. To visualize in vivo CD19 expression noninvasively, we radiolabeled anti-human CD19 monoclonal antibodies with copper-64 (⁶⁴Cu-αCD19) for positron emission tomography (CD19-immunoPET). ⁶⁴Cu-αCD19 specifically bound to subcutaneous Daudi xenograft mouse models in vivo. Importantly, ⁶⁴Cu-αCD19 did not affect the anti-lymphoma cytotoxicity of CD19 CAR-T cells in vitro. Following our preclinical validation, ⁶⁴Cu-αCD19 was injected into four patients with follicular lymphoma, diffuse large B-cell lymphoma or mantle zone lymphoma. We observed varying ⁶⁴Cu-αCD19 PET uptake patterns at different lymphoma sites, both within and among patients, correlating with ex vivo immunohistochemical CD19 expression. Moreover, one patient exhibited enhanced uptake in the spleen compared to that in patients with prior B-cell-depleting therapy, indicating that ⁶⁴Cu-αCD19 is applicable for identifying B-cell-rich organs. In conclusion, we demonstrated the specific targeting and visualization of CD19⁺ B-NHL in mice and humans by CD19-immunoPET. The intra- and interindividual heterogeneous ⁶⁴Cu-αCD19 uptake patterns of lymphoma lesions indicate variability in CD19 expression, suggesting the potential of CD19-immunoPET as a novel tool to guide CD19-directed therapies.

Supplementary Information

The online version contains supplementary material available at 10.1186/s40364-024-00595-9.

To the editor

CD19-directed therapies, such as chimeric antigen receptor (CAR)-T cells, the Fc receptor-optimized monoclonal antibody (mAb) Tafasitamab-cxix or the mAb-drug conjugate Loncastuximab tesirine, have emerged as relevant treatment alternatives for B-cell non-Hodgkin lymphoma (B-NHL). While some patients achieve complete and durable remission, the overall response rate of ∼ 50% falls considerably below that observed in Pro-B-ALL patients. Furthermore, 70% of B-NHL patients fail to achieve long-term survival, exposing them to significant toxicity, particularly neurotoxicity or cytokine release syndrome [1–5].

In contrast to single-cell leukemia targeting, challenges such as impaired lymphoma cell accessibility, a complex immunosuppressive microenvironment, inter- and intraindividual alterations in CD19 expression, CD19 epitope loss or downregulation following CD19-directed therapy, and unreliable immunohistochemical CD19 staining limit accurate patient stratification and therapeutic success in B-NHL patients [6–9]. Beyond histopathological assessment, there is currently no target-specific approach available that can be used for patient stratification and treatment decision-making in B-NHL.

Positron emission tomography (PET) with radiolabeled antibodies (immunoPET) enables whole-body visualization and quantification of specific target expression over time, therapeutic drug biodistribution, and tumor accessibility [10]. Recently, we revealed heterogeneous GD2-derived uptake patterns and distinct alterations during targeted therapy in pediatric patients with metastatic neuroblastoma and sarcoma using a radiolabeled anti-GD2-mAb [11, 12]. In this study, we developed a copper-64 (⁶⁴Cu)-radiolabeled mAb directed against human CD19 for positron emission tomography (PET) imaging and demonstrated, for the first time, the specific in vivo targeting and noninvasive visualization of CD19⁺ lymphoma lesions in experimental lymphoma-bearing mice and four human B-NHL subjects.

Radiolabeling of the αCD19-mAb (⁶⁴Cu-αCD19) yielded a stable radioimmunoconjugate with minimal dimerization, high radiochemical (> 95%) and radionuclidic purity (≥ 99.9%), and an immunoreactivity of 57% (Fig. S1a, b). In vivo PET/MR and ex vivo biodistribution demonstrated significantly greater ⁶⁴Cu-αCD19 uptake in subcutaneous Daudi lymphoma xenografts compared to a ⁶⁴Cu-αB7-H3 control tracer (Fig. 1a, b; Fig. S1c). Importantly, the αCD19-mAb impaired αCD19-CAR-T-cell-mediated cytotoxicity in vitro only at concentrations ∼ 1000 times greater than the applied dose for PET imaging (Fig. 1c).

Fig. 1.

Preclinical evaluation of ⁶⁴Cu-αCD19 and potential epitope blocking. (a) Representative transversal PET/MR (fused) as well as single MR and PET images of CD1 nude mice subcutaneously injected with Daudi lymphomas 48 h post-i.v. administration of ⁶⁴Cu-αCD19 or unrelated isotype control (⁶⁴Cu-αB7-H3). Lymphoma sites are marked by white arrows. (b) PET quantification of lymphoma uptake calculated as %ID/cc (in vivo) or %ID/g (ex vivo) and tumor-to-muscle ratios (n = 4–5 per group, unpaired t test, P values < 0.05 (*) were considered statistically significant). (c) Potential epitope blocking by αCD19-mAb and consecutive functional impairment of αCD19-CAR-T cells were tested in cytotoxicity assays against the CD19-expressing NHL cell line JeKo-1. αCD19-mAb dose titration demonstrated functional blocking effects at a concentration of 100 µg/ml (upper blot). CD19KO lymphoma cells served as a control to exclude target-independent effects (lower blot). (n = 12 per concentration, ordinary ANOVA, corrected for multiple comparison using the Tukey test, (****) P < 0.0001). The concentration of 0.1 µg/ml (blue) was calculated as the blood and lymphoma lesions based on the clinical PET/MR data

First-in-human PET/MRI scans were conducted ∼ 24 h after ⁶⁴Cu-αCD19 injection in four B-NHL patients to evaluate eligibility for CD19-directed therapies (Fig. 2). As expected from previous therapeutic applications in childhood B-ALL patients treated with substantially higher mAb doses, all patients tolerated the ⁶⁴Cu-αCD19 injections without any obvious clinical signs of toxicity.

Fig. 2.

First-in-human application of ⁶⁴Cu-αCD19. CD19-immunoPET was performed on four lymphoma patients [1–4] with different histological subtypes 19–25 h after ⁶⁴Cu-αCD19 injection. Left: Immunohistochemical analysis of CD19 protein expression (CD19-IHC) in lymphoma tissues and maximum intensity projection (MIP) of standardized uptake values (SUV) for each patient. FL = follicular lymphoma, DLBCL = diffuse large B-cell lymphoma, MZL = mantle zone lymphoma, LN = lymph node. a-l. Exemplary transversal images (levels are marked in the MIP by red lines) of different lymphoma lesions (indicated by white arrows) and spleens (green arrow) are shown for each patient

Patient 1, with double-hit follicular lymphoma, exhibited remarkable tracer uptake in the cervical, abdominal, and singular bone lymphoma manifestations (Fig. 2a-c; average standardized uptake value, SUVavg 7.7–8.5). Interestingly, all lesions could be better differentiated by CD19-immunoPET than by [¹⁸F]FDG-PET/CT conducted 90 days before (Fig. S2a-c). Immunohistochemistry of a previously extirpated cervical lymph node revealed moderate CD19 protein expression. In contrast, the abdominal lymphoma bulk, irradiated by a total fractionated dose of 30 Gy with palliative intent shortly before, yielded little tracer accumulation (Fig. S2b; SUVavg < 1.5), suggesting residual necrotic/avital tissue.

In Patient 2, who suffered from refractory DLBCL, the thoracic (Fig. 2d) and abdominal lymphoma manifestations (Fig. 2d-f) indicated the strongest ⁶⁴Cu-αCD19 accumulation among all the subjects (SUVavg up to 27.7). Likewise, intense histological CD19 expression was found in the resectate of a peritoneal lymphoma conglomerate. Furthermore, we detected markedly greater tracer uptake in the spleen (SUVavg 21.7) than in the other three patients (SUVavg 5.1–8.5). Notably, Patient 2 was the only subject who did not receive the B-cell-depleting αCD20-mAb rituximab within the last 6 months prior to CD19-immunoPET, indicating that ⁶⁴Cu-αCD19 is applicable for detecting physiological B cells in lymphatic organs.

We further revealed pronounced tracer accumulation in the bone marrow of Patient 3 with DLBCL (Fig. 2h) compared to the other B-NHL patients (SUVavg 12.7 vs. 5.0, Patient 1). Interestingly, a subsequent bone marrow biopsy showed 99% B-NHL infiltration with intense CD19 expression, demonstrating the ability of CD19-ImmunoPET to differentiate CD19⁺ lymphoma lesions. However, we detected faint uptake in the known retrosternal and iliacal lesions (Fig. 2g, i) of Patient 3, which were highly suspicious of vital lymphoma according to [¹⁸F]FDG-PET/CT (Fig. S5d, f).

Moreover, in line with the low histological CD19 expression in an extirpated cervical lymph node from initial diagnosis, Patient 4, with marginal zone lymphoma, exhibited slight ⁶⁴Cu-αCD19 uptake in the margin of a large pulmonary lymphoma bulk (Fig. 2j) and no relevant PET-derived signal in the retroperitoneal manifestations (Fig. 2l).

In conclusion, for the first time, we demonstrated the feasibility of detecting CD19⁺ lymphoma lesions noninvasively by CD19-immunoPET in B-NHL patients, which is fully consistent with the findings of our preclinical mouse studies. This innovative imaging approach may improve both patient stratification and therapeutic surveillance by detecting heterogeneous CD19 expression or antigen downregulation during CD19-directed therapies.

Furthermore, the noninvasive visualization of endogenous B cells holds great promise in multiple sclerosis [13] or for targeting tumor-associated tertiary lymphatic structures [14]. Finally, prospective clinical studies are needed to validate the optimal tracer dose, the accuracy of ⁶⁴Cu-αCD19 uptake, the influence of physiological B cells on the PET uptake, potential tracer-related toxicities, and the superiority of this approach over conventional CD19 histopathology.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Abbreviations

⁶⁴Cu

copper-64

B-NHL

B-cell non-Hodgkin lymphoma

CD19

cluster of differentiation 19

CT

computed tomography

DLBCL

diffuse large B-cell lymphoma

FDG

< Superscript>18</Superscript> F-fluorodeoxyglucose

mAb

monoclonal antibody

MRI

magnetic resonance imaging

PET

positron emission tomography

SUVavg

average standardized uptake value

Author contributions

DS, JSchm, RH, MK, ClF, and BP conceived and designed the research. DS, SB, and JSchm conducted the preclinical experiments and analyzed the data. AM, WE, and GR performed the radiolabeling. MR and JSk generated the KO cell lines. GJ, PL, and RH developed the GMP-αCD19-mAb. JSchw, and ClF performed the clinical imaging. SK and CS conducted the cytotoxicity assay. FF contributed to the CD19 immunohistochemistry. MK, GR, RH, ClF, and BP supervised the study and interpreted the results. DS, SB, JSchw, AM, MK, ClF, and BP wrote the manuscript. All the authors reviewed and edited the manuscript and approved the final version of the manuscript.

Funding

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy - EXC 2180 - 390900677) and the Swiss Werner Siemens Foundation funded these experiments. The Förderverein und Stiftung für krebskranke Kinder Tübingen, Aktion Erna and Hilfe für krebskranke Kinder Frankfurt e.V. are gratefully acknowledged for their financial support in the GMP production of the αCD19-mAb.

Data availability

For original data, please contact Dominik.Sonanini@med.uni-tuebingen.de (preclinical data) or Christian.laFougere@med.uni-tuebingen.de (clinical data).

Declarations

Ethics approval and consent to participate

All subjects provided written consent according to national regulations and the Declaration of Helsinki. The evaluation of patient data was approved by the ethics committee of the University of Tübingen (533/2021BO2).

Consent for publication

All authors agreed on the publication of the manuscript.

Competing interests

The authors declare that no conflicts of interest exist.